The Polish Society of Gynecological Oncology Guidelines for the Diagnosis and Treatment of Endometrial Carcinoma (2023)

Author:

Sznurkowski Jacek J.1ORCID,Rys Janusz2,Kowalik Artur34ORCID,Zolciak-Siwinska Agnieszka5,Bodnar Lubomir6ORCID,Chudecka-Glaz Anita7,Blecharz Pawel8,Zielinska Aleksandra9ORCID,Marszalek Andrzej1011,Bidzinski Mariusz5ORCID,Sawicki Wlodzimierz9ORCID

Affiliation:

1. Department of Surgical Oncology, Medical University of Gdansk, ul. Smoluchowskiego 17, 80-214 Gdańsk, Poland

2. Department of Tumor Pathology, Maria Sklodowska-Curie National Research Institute of Oncology, Kraków Branch, 44-102 Kraków, Poland

3. Department of Molecular Diagnostics, Holy Cross Cancer Center, 25-735 Kielce, Poland

4. Division of Medical Biology, Institute of Biology, Jan Kochanowski University, 25-406 Kielce, Poland

5. Department of Gynaecological Oncology, Maria Sklodowska-Curie National Research Institute of Oncology, 00-001 Warsaw, Poland

6. Faculty of Medical and Health Sciences, Siedlce University of Natural Sciences and Humanities, 08-110 Siedlce, Poland

7. Department of Gynecological Surgery and Gynecological Oncology of Adults and Adolescents, Pomeranian Medical University, 70-111 Szczecin, Poland

8. Department of Gynaecologic Oncology, Maria Sklodowska-Curie National Research Institute of Oncology, Krakow Branch, 44-102 Kraków, Poland

9. Department of Obstetrics and Gynecological Oncology, Medical University of Warsaw, 00-575 Warsaw, Poland

10. Department of Tumor Pathology and Prophylaxis, Poznan University of Medical Sciences, 61-701 Poznan, Poland

11. Department of Tumor Pathology, Greater Poland Cancer Center in Poznan, 61-866 Poznan, Poland

Abstract

Background: Due to the increasing amount of published data suggesting that endometrial carcinoma is a heterogenic entity with possible different treatment sequences and post-treatment follow-up, the Polish Society of Gynecological Oncology (PSGO) has developed new guidelines. Aim: to summarize the current evidence for diagnosis, treatment, and follow-up of endometrial carcinoma and to provide evidence-based recommendations for clinical practice. Methods: The guidelines have been developed according to standards set by the guideline evaluation tool AGREE II (Appraisal of Guidelines for Research and Evaluation). The strength of scientific evidence has been defined in agreement with The Agency for Health Technology Assessment and Tariff System (AOTMiT) guidelines for scientific evidence classification. The grades of recommendation have been based on the strength of evidence and the level of consensus of the PSGO development group. Conclusion: Based on current evidence, both the implementation of the molecular classification of endometrial cancer patients at the beginning of the treatment sequence and the extension of the final postoperative pathological report of additional biomarkers are needed to optimize and improve treatment results as well as to pave the route for future clinical trials on targeted therapies.

Publisher

MDPI AG

Subject

General Medicine

Reference96 articles.

1. AGREE II: Advancing guideline development, reporting and evaluation in health care;Brouwers;CMAJ,2010

2. Wytyczne Przeprowadzania Oceny Technologii Medycznych (HTA) (2023, February 08). Załącznik do Zarządzenia nr 40/2016 Prezesa AOTMiT Oceny Technologii Medycznych i Taryfikacji z dnia 13 września 2016 r. w Sprawie Wytycznych Oceny Świadczeń Opieki Zdrowotnej, Available online: https://www.aotm.gov.pl/media/2020/07/20160913_Wytyczne_AOTMiT-1.pdf.

3. WHO Classification of Tumours (2020). Edditorial Board. Female Genital Tumours, International Agency for Research on Cancer. [5th ed.].

4. Molecular genetics of endometrial carcinoma;Bell;Annu. Rev. Pathol.,2019

5. Deolet, E., Van Dorpe, J., and Van de Vijver, K. (2021). Mesonephric-like adenocarcinoma of the endometrium: Diagnostic advances to spot this wolf in sheep’s clothing. A Review of the literature. J. Clin. Med., 10.

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3